Table 1.

Characteristics of ovarian cancer cases and controls in a nested case–control study in the PLCO Cancer Screening Trial

Control (N = 156)Ovarian cancer cases (N = 157)
Na (%)Na (%)
Age at randomization
 ≤59 years46 (29.5)46 (29.3)
 60–64 years46 (29.5)46 (29.3)
 65–69 years40 (25.6)41 (26.1)
 ≥70 years24 (15.4)24 (15.3)
Race
 Non-Hispanic white144 (92.3)144 (91.7)
 Non-Hispanic black, Hispanic, Asian12 (7.7)13 (8.3)
Highest education level attained
 High school or less49 (31.4)45 (29.0)
 Some post-high school training52 (33.3)55 (35.0)
 College graduate55 (35.1)57 (36.3)
BMI
 <25 kg/m266 (42.3)66 (42.6)
 25–29.9 kg/m254 (35.0)56 (36.1)
 ≥30 kg/m236 (23.1)33 (21.3)
Cigarette smoking status
 Never101 (64.7)84 (53.5)
 Former17 (10.9)12 (7.6)
 Current38 (24.3)61 (38.8)
Age at menarche
 <11 years27 (17.1)34 (21.7)
 12–13 years80 (51.3)89 (56.7)
 13+ years49 (31.2)34 (21.7)
Parity
 Nulliparous149 (95.0)146 (93.0)
 Parous8 (5.1)11 (7.0)
Duration of oral contraceptive use
 Never or <1 year77 (49.4)86 (54.8)
 1–5 years50 (32.0)48 (30.6)
 6+ years29 (18.6)23 (14.6)
Regularly uses aspirin or ibuprofen
 Does not use aspirin or ibuprofen66 (43.0)55 (35.0)
 Does not use aspirin but uses ibuprofen21 (13.5)25 (16.0)
 Uses aspirin but not ibuprofen44 (28.4)53 (34.0)
 Uses both aspirin and ibuprofen24 (15.5)24 (15.4)
Duration of menopausal hormone therapy use
 Never or <1 year63 (41.0)45 (28.7)
 1–5 years48 (30.7)50 (32.0)
 6+ years45 (28.8)62 (39.5)
  • aValues may not sum to total because of missing data.